Denali Therapeutics (DNLI) Accumulated Depreciation & Amortization (2017 - 2025)

Denali Therapeutics (DNLI) has 9 years of Accumulated Depreciation & Amortization data on file, last reported at $11.2 million in Q4 2025.

• Quarterly Accumulated Depreciation & Amortization rose 43.59% year-over-year to $11.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.2 million (up 43.59% YoY) and the FY2025 annual result came in at $11.2 million, up 43.59% from the prior year.
• Accumulated Depreciation & Amortization rose to $11.2 million in Q4 2025 per DNLI's latest filing, from $7.8 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $16.7 million in Q4 2023 and bottomed at $7.8 million in Q4 2024.
• The 5-year median for Accumulated Depreciation & Amortization is $10.4 million (2022), against an average of $10.9 million.
• The widest annual swing landed in 2023, when Accumulated Depreciation & Amortization soared 60.84%; it then sank 53.29% in 2024.
• Tracing DNLI's Accumulated Depreciation & Amortization over 5 years: stood at $8.6 million in 2021, then advanced by 20.73% to $10.4 million in 2022, then jumped by 60.84% to $16.7 million in 2023, then slumped by 53.29% to $7.8 million in 2024, then surged by 43.59% to $11.2 million in 2025.
• Per Business Quant, the three latest DNLI Accumulated Depreciation & Amortization figures stand at $11.2 million (Q4 2025), $7.8 million (Q4 2024), and $16.7 million (Q4 2023).

Peer Comparison